Parkinson's Disease Clinical Trial Pipeline Boom as 150+ Companies are in the Race for Better Treatments | DelveInsight
The Parkinson's disease clinical trial analysis report delivers important insights into ongoing research of 200+ pipeline Parkinson's disease drugs, clinical strategies, upcoming therapeutics, and commercial analysis.
New York, USA, July 16, 2026 (GLOBE NEWSWIRE) -- Parkinson's Disease Clinical Trial Pipeline Boom as 150+ Companies are in the Race for Better Treatments | DelveInsight
The Parkinson's disease clinical trial analysis report delivers important insights into ongoing research of 200+ pipeline Parkinson's disease drugs, clinical strategies, upcoming therapeutics, and commercial analysis.
DelveInsight’s 'Parkinson's Disease Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for Parkinson's disease across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the Parkinson's disease domain.
Parkinson's Disease Clinical Trial Analysis Summary
- DelveInsight’s Parkinson's disease pipeline report depicts a robust space with 150+ active players working to develop 200+ pipeline Parkinson's disease drugs.
- Key Parkinson's disease companies, such as NeuroDerm, Ltd., Annovis Bio, Cerevance, Alto Neuroscience, Integrative Research Laboratories, AlzeCure, Muna Therapeutics, Biogen, Denali Therapeutics, FAScinate Therapeutics, AC Immune, iRegene Therapeutics, Hillhurst Biopharmaceuticals, Olatec Therapeutics LLC, TrueBinding, Asklepios BioPharmaceutical (Bayer), Guangzhou Henovcom Bioscience, Mthera Pharma, Bioarctic Pharma, Lundbeck, Neuraly, Sinopia Biosciences, Seelos Therapeutics Serina Therapeutics, Structure Therapeutics, Amphix Bio, Neumora, Arrowhead Pharmaceuticals, Kazia Therapeutics, Lys Therapeutics, Acurex Biosciences, and others, are evaluating new Parkinson's disease drugs to improve the treatment landscape.
- Promising pipeline Parkinson's disease therapies, such as ND0612, Buntanetap, CVN424, ALTO-208, Pirepemat, ACD-856, Research program: Kv1.3 blockade, DNL151, KM-819, ACI 7104.056, NouvNeu001, HBI-002, Dapansutrile, TB006, AB-1005 (AAV2-GDNF), HNC364, MT101, Exidavnemab, Lu AF82422, NLY01, SB-0110, SLS 004, SER-252, GSBR-5595, Research program, NMRA-CK1δ, ARO-SNCA, Paxalisib, Research program, Research program: Selective CaV3.2 Antagonist, and others, are in different phases of Parkinson's disease clinical trials.
- Approximately 11+ Parkinson's disease drugs are in the late stages of development.
- Notable MoAs in Parkinson's disease clinical trials include Decarboxylase inhibitors, Dopamine receptor agonists, Alpha-synuclein inhibitors, Tau protein inhibitors, GPR6 protein inhibitors, Dopamine D2 receptor agonists, Dopamine D3 receptor agonists, Neurokinin 1 receptor antagonists, 5HT7 receptor antagonist, alpha-2 receptor antagonist, Bcr-Abl tyrosine kinase inhibitors, Trk-receptors modulator, Kv1.3 channel blocker, and others.
Request a sample and discover the recent advances in Parkinson's disease drug development @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights
What is Parkinson's Disease?
Parkinson's disease is a progressive neurological condition that primarily affects movement due to the gradual loss of dopamine-producing neurons in a region of the brain called the substantia nigra. This decline in dopamine disrupts normal communication within the brain, leading to hallmark symptoms such as tremors at rest, muscle rigidity, slowed movements, and impaired balance and coordination. In addition to motor symptoms, patients may also experience non-motor issues like depression, sleep disturbances, cognitive changes, and autonomic dysfunction. Although the exact cause is not fully understood, a combination of genetic and environmental factors is believed to contribute. While there is currently no cure, treatments, including medications like Levodopa and surgical interventions, can help manage symptoms and improve quality of life.
Find out more about Parkinson's disease drug development @ Parkinson's Disease Treatment
A snapshot of the Pipeline Parkinson's Disease Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| Buntanetap | Annovis Bio | III | Alpha-synuclein inhibitors; Tau protein inhibitors | Oral |
| CVN424 | Cerevance | III | GPR6 protein inhibitors | Oral |
| ALTO-208 | Alto Neuroscience | II | Dopamine D2 receptor agonists; Dopamine D3 receptor agonists; Neurokinin 1 receptor antagonists | Oral |
| Pirepemat | Integrative Research Laboratories | II | 5HT7 receptor antagonist; alpha-2 receptor antagonist | Oral |
| ACD-856 | AlzeCure | I | Trk-receptors modulator | Oral |
| Research program: Kv1.3 blockade | Muna Therapeutics | Preclinical | Kv1.3 channel blocker | NA |
Learn more about the emerging Parkinson's disease therapies @ Parkinson's Disease Clinical Trials
As per Stuti Mahajan, consulting manager at DelveInsight, Parkinson’s disease remains a significant unmet medical need, driven by its progressive neurodegenerative nature and increasing prevalence in aging populations. Current therapies primarily provide symptomatic relief, highlighting the need for disease-modifying treatments that can slow or halt disease progression. Advances in biomarkers, gene therapies, and novel neuroprotective approaches are expected to reshape the treatment landscape and improve long-term patient outcomes.
Recent Developments in Parkinson's Disease Treatment Space
- In May 2026, Biogen and Denali Therapeutics announced topline results from the Phase IIb LUMA study evaluating BIIB122 (DNL151), an investigational small molecule inhibitor of LRRK2 (leucine-rich repeat kinase 2), in individuals with early-stage Parkinson’s disease.
- In May 2026, Cerevance announced completion of patient enrollment in the pivotal Phase III ARISE trial evaluating solengepras in Parkinson’s disease and the closing of a USD 20 million Series C financing round. The ARISE trial enrolled 341 patients across the United States, Europe, United Kingdom, and Australia, and is assessing solengepras as an adjunctive therapy to levodopa and other standard-of-care Parkinson’s medications in patients who experience motor fluctuations, including daily OFF periods.
- In May 2026, Jupiter Neurosciences announced that patient enrollment is now underway in its Phase IIa RESET clinical trial (NCT07592767) for JOTROL™ (investigational trans-resveratrol micellar formulation) in Parkinson’s Disease, with first patient dosing expected in the near term.
- In March 2026, Aspen Neuroscience announced data from its ongoing Phase I/IIa ASPIRO* clinical trial in a late-breaking oral presentation at the AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases, held March 17–21, 2026, in Copenhagen, Denmark. The presentation highlighted 12-month safety, tolerability, and efficacy data following the delivery of Sasineprocel (ANPD001), an autologous induced pluripotent stem cell (iPSC)-derived dopaminergic neuron precursor cell therapy (DANPC), in patients with Parkinson's disease without the need for immunosuppression or permanent implantable hardware.
- In January 2026, iRegene Therapeutics announced that its lead product, NouvNeu001, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration for the treatment of Parkinson's disease.
- In October 2025, Arrowhead Pharmaceuticals, Inc. announced that a global licensing and collaboration agreement with Novartis, previously announced in September 2025, has now closed.
- In September 2025, BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, announced that the first patient had received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of bemdaneprocel, an investigational cell therapy for Parkinson’s disease.
- In June 2025, Roche announced its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson’s disease. This decision is informed by data from the Phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PADOVA and Phase II PASADENA studies.
Scope of the Parkinson's Disease Pipeline Report
- Coverage: Global
- Parkinson's Disease Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Parkinson's Disease Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Parkinson's Disease Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
- Parkinson's Disease Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
- Parkinson's Disease Therapeutics Assessment By Mechanism of Action: Decarboxylase inhibitors, Dopamine receptor agonists, Alpha-synuclein inhibitors, Tau protein inhibitors, GPR6 protein inhibitors, Dopamine D2 receptor agonists, Dopamine D3 receptor agonists, Neurokinin 1 receptor antagonists, 5HT7 receptor antagonist, alpha-2 receptor antagonist, Bcr-Abl tyrosine kinase inhibitors, Trk-receptors modulator, Kv1.3 channel blocker, and others
- Key Parkinson's Disease Companies: NeuroDerm, Ltd., Annovis Bio, Cerevance, Alto Neuroscience, Integrative Research Laboratories, AlzeCure, Muna Therapeutics, Biogen, Denali Therapeutics, FAScinate Therapeutics, AC Immune, iRegene Therapeutics, Hillhurst Biopharmaceuticals, Olatec Therapeutics LLC, TrueBinding, Asklepios BioPharmaceutical (Bayer), Guangzhou Henovcom Bioscience, Mthera Pharma, Bioarctic Pharma, Lundbeck, Neuraly, Sinopia Biosciences, Seelos Therapeutics Serina Therapeutics, Structure Therapeutics, Amphix Bio, Neumora, Arrowhead Pharmaceuticals, Kazia Therapeutics, Lys Therapeutics, Acurex Biosciences, and others.
- Key Parkinson's Disease Pipeline Therapies: ND0612, Buntanetap, CVN424, ALTO-208, Pirepemat, ACD-856, Research program: Kv1.3 blockade, DNL151, KM-819, ACI 7104.056, NouvNeu001, HBI-002, Dapansutrile, TB006, AB-1005 (AAV2-GDNF), HNC364, MT101, Exidavnemab, Lu AF82422, NLY01, SB-0110, SLS 004, SER-252, GSBR-5595, Research program, NMRA-CK1δ, ARO-SNCA, Paxalisib, Research program, Research program: Selective CaV3.2 Antagonist, and others.
Dive deep into rich insights for new Parkinson's disease treatments, visit @ Parkinson's Disease Drugs
Table of Contents
| 1. | Parkinson's Disease Pipeline Report Introduction |
| 2. | Parkinson's Disease Pipeline Report Executive Summary |
| 3. | Parkinson's Disease Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Parkinson's Disease Clinical Trial Therapeutics |
| 6. | Parkinson's Disease Pipeline: Late-Stage Products (Pre-registration) |
| 7. | Parkinson's Disease Pipeline: Late-Stage Products (Phase III) |
| 8. | Parkinson's Disease Pipeline: Mid-Stage Products (Phase II) |
| 9. | Parkinson's Disease Pipeline: Early-Stage Products (Phase I) |
| 10. | Parkinson's Disease Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Parkinson's Disease Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Parkinson's Disease Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the Parkinson's disease cure research, reach out @ Medication for Parkinson's Disease Treatment
Related Reports
Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson’s disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, Cerevance, and others.
Cell and Gene Therapy in Parkinson's Disease Market
Cell and Gene Therapy in Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cell and gene therapy in Parkinson's disease companies including MeiraGTx, Hope Biosciences, Sumitomo Pharma, Prevail Therapeutics, BlueRock Therapeutics, Voyager Therapeutics, and others.
Parkinson's Disease Psychosis Market
Parkinson's Disease Psychosis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson’s disease psychosis companies, including Sumitomo Pharma America Inc., Vanda Pharmaceuticals, Acadia Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Sio Gene Therapies, Axovant Sciences Ltd, and others.
Parkinson’s Disease-Related Dementia Market
Parkinson's Disease-Related Dementia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson’s disease-related dementia companies, including AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., and others.
Psychosis in Parkinson’s and Alzheimer’s Disease Market
Psychosis in Parkinson’s and Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson’s and Alzheimer’s disease companies, including Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us Shruti Thakur info@delveinsight.com +14699457679
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
